Literature DB >> 29752314

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Wei Xiao1, John D Klement1,2,3, Chunwan Lu1,2,3, Mohammed L Ibrahim1,2, Kebin Liu4,2,3.   

Abstract

Tumor cells respond to IFN-γ of activated T cells to upregulate programmed death-ligand 1 (PD-L1) in the tumor microenvironment as an adaptive immune resistance mechanism. Tumor cells also express oncogene-driven PD-L1. PD-L1 is also expressed on myeloid-derived suppressor cells (MDSCs). It is known that both type I and II IFNs upregulate PD-L1 expression in MDSCs. However, the molecular mechanism underlying PD-L1 expression in MDSCs is still largely unknown. We report in this article that MDSCs exhibit constitutive STAT1 phosphorylation in vitro without exogenous IFNs, indicating a constitutive active JAK-STAT signaling pathway in mouse MDSCs in vitro. Furthermore, IFN-α and IFN-β but not IFN-γ are endogenously expressed in the MDSC cell line in vitro and in tumor-induced MDSCs in vivo. Neutralizing type I IFN or inhibiting the JAK-STAT signaling pathway significantly decreased constitutive PD-L1 expression in MDSCs in vitro. However, neither IFN-α expression level nor IFN-β expression level is correlated with PD-L1 expression level in MDSCs; instead, the level of IFN receptor type I (IFNAR1) is correlated with PD-L1 expression levels in MDSCs. Consequently, knocking out IFNAR1 in mice diminished PD-L1 expression in tumor-induced MDSCs. Therefore, we determined that 1) PD-L1 expression in MDSCs is activated by type I IFN through an autocrine manner and 2) the expression level of PD-L1 is controlled at least in part by the IFNAR1 level on MDSCs. Our data indicate that MDSCs may maintain their PD-L1 expression via autocrine type I IFN to exert their suppressive activity in the absence of IFN-γ from the suppressed T cells in the tumor microenvironment.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29752314      PMCID: PMC6008224          DOI: 10.4049/jimmunol.1800129

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.

Authors:  Taku Fujimura; Sabine Ring; Viktor Umansky; Karsten Mahnke; Alexander H Enk
Journal:  J Invest Dermatol       Date:  2011-12-22       Impact factor: 8.551

4.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

5.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

Review 6.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

7.  Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.

Authors:  Tobias Bald; Jennifer Landsberg; Dorys Lopez-Ramos; Marcel Renn; Nicole Glodde; Philipp Jansen; Evelyn Gaffal; Julia Steitz; Rene Tolba; Ulrich Kalinke; Andreas Limmer; Göran Jönsson; Michael Hölzel; Thomas Tüting
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

Review 8.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

Review 9.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  25 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

Review 2.  Tumor microenvironment antigens.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2022-09-29       Impact factor: 11.759

Review 3.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 4.  Myeloid-derived suppressor cells in COVID-19: A review.

Authors:  Yuliya V Perfilyeva; Yekaterina O Ostapchuk; Raikhan Tleulieva; Aykin Kali; Nurshat Abdolla; Vladimir K Krasnoshtanov; Anastassiya V Perfilyeva; Nikolai N Belyaev
Journal:  Clin Immunol       Date:  2022-04-27       Impact factor: 10.190

Review 5.  Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.

Authors:  Daniele Lecis; Sabina Sangaletti; Mario P Colombo; Claudia Chiodoni
Journal:  Cancers (Basel)       Date:  2019-05-04       Impact factor: 6.639

Review 6.  The Tumor Microenvironment in Colorectal Cancer Therapy.

Authors:  Leire Pedrosa; Francis Esposito; Timothy M Thomson; Joan Maurel
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

7.  Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.

Authors:  Chunwan Lu; John D Klement; Mohammed L Ibrahim; Wei Xiao; Priscilla S Redd; Asha Nayak-Kapoor; Gang Zhou; Kebin Liu
Journal:  J Immunother Cancer       Date:  2019-06-22       Impact factor: 13.751

Review 8.  Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.

Authors:  Hadia Farrukh; Nader El-Sayes; Karen Mossman
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

9.  Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

Authors:  Eleni Panagioti; Cheyne Kurokawa; Kimberly Viker; Arun Ammayappan; S Keith Anderson; Sotiris Sotiriou; Kyriakos Chatzopoulos; Katayoun Ayasoufi; Aaron J Johnson; Ianko D Iankov; Evanthia Galanis
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

Review 10.  Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.

Authors:  Yuhui Yang; Chunyan Li; Tao Liu; Xiaofang Dai; Alexandr V Bazhin
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.